Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 4/2016

01.04.2016 | Movement Disorders (S Fox, Section Editor)

Integrated Approach for Pain Management in Parkinson Disease

verfasst von: Christian Geroin, Marialuisa Gandolfi, Veronica Bruno, Nicola Smania, Michele Tinazzi

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Pain, one of the most frequent nonmotor symptoms of Parkinson disease (PD), is recognized as an important component of the illness that adversely affects patient quality of life. The aims of this review are to summarize the current knowledge on the clinical assessment and to provide a detailed overview of the evidence-based pharmacologic and nonpharmacologic approaches to treating pain. Results of a literature search include studies investigating pain/sensory abnormalities in PD. The effects of levodopa administration, deep brain stimulation (DBS), pallidotomy, spinal cord stimulation, rehabilitation, and complementary/alternative medicine are reviewed critically. PD patients have altered pain and sensory thresholds; levodopa and DBS improve pain and change sensory abnormalities toward normal levels through antinociceptive and/or modulatory effects that remain unknown. A wide range of nonpharmacologic approaches require further investigation. A multidisciplinary approach is fundamental in managing pain syndromes in PD.
Literatur
1.
Zurück zum Zitat Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson’s disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10:129–36.CrossRefPubMed Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson’s disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10:129–36.CrossRefPubMed
2.
Zurück zum Zitat Mao CJ, Chen JP, Zhang XY, Liu CF, et al. Parkinson’s disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci. 2015;36:263–8.CrossRefPubMed Mao CJ, Chen JP, Zhang XY, Liu CF, et al. Parkinson’s disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci. 2015;36:263–8.CrossRefPubMed
3.
4.
Zurück zum Zitat Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland; 1817. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland; 1817.
5.
Zurück zum Zitat Ford B. Pain in Parkinson disease: the hidden epidemic visual rating of atrophy aids diagnostic accuracy. Nat Rev Neurol. 2009;5:242–3.CrossRefPubMed Ford B. Pain in Parkinson disease: the hidden epidemic visual rating of atrophy aids diagnostic accuracy. Nat Rev Neurol. 2009;5:242–3.CrossRefPubMed
7.
Zurück zum Zitat Toda K, Harada T. Prevalence, classification, and etiology of pain in Parkinson’s disease: association between Parkinson’s disease and fibromyalgia or chronic widespread pain. Tohoku J Exp Med. 2010;222:1–5.CrossRefPubMed Toda K, Harada T. Prevalence, classification, and etiology of pain in Parkinson’s disease: association between Parkinson’s disease and fibromyalgia or chronic widespread pain. Tohoku J Exp Med. 2010;222:1–5.CrossRefPubMed
8.••
Zurück zum Zitat Defazio G, Gigante A, Mancino P, Tinazzi M. The epidemiology of pain in Parkinson’s disease. J Neural Transm. 2013;120:583–6. Defazio et al. reviewed the literature on pain epidemiology in PD patients. They showed that pain affects a large population of patients and should be considered a nonmotor symptom. This study shows that different qualities of pain may be present in PD and that there is a variable relationship between pain and motor signs and the response to dopaminergic medications.CrossRefPubMed Defazio G, Gigante A, Mancino P, Tinazzi M. The epidemiology of pain in Parkinson’s disease. J Neural Transm. 2013;120:583–6. Defazio et al. reviewed the literature on pain epidemiology in PD patients. They showed that pain affects a large population of patients and should be considered a nonmotor symptom. This study shows that different qualities of pain may be present in PD and that there is a variable relationship between pain and motor signs and the response to dopaminergic medications.CrossRefPubMed
9.
Zurück zum Zitat Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–4.CrossRefPubMed Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–4.CrossRefPubMed
10.
Zurück zum Zitat Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65:1191–4.CrossRefPubMed Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65:1191–4.CrossRefPubMed
11.
Zurück zum Zitat Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O, DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23:1361–9.CrossRefPubMed Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O, DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23:1361–9.CrossRefPubMed
12.
Zurück zum Zitat Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol. 2011;258:627–33.CrossRefPubMed Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol. 2011;258:627–33.CrossRefPubMed
13.
Zurück zum Zitat Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22:853–6.CrossRefPubMed Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22:853–6.CrossRefPubMed
14.
Zurück zum Zitat Vela L, Facca A, Lyons KE, Lieberman AN. Pain and Parkinson’s disease. Mov Disord. 2002;17:S154–5.CrossRef Vela L, Facca A, Lyons KE, Lieberman AN. Pain and Parkinson’s disease. Mov Disord. 2002;17:S154–5.CrossRef
15.
Zurück zum Zitat Goetz CG, Tanner CM, Lewy M, et al. Pain in Parkinson’s disease. Mov Disord. 1986;1:45–9.CrossRefPubMed Goetz CG, Tanner CM, Lewy M, et al. Pain in Parkinson’s disease. Mov Disord. 1986;1:45–9.CrossRefPubMed
16.
Zurück zum Zitat McNamara P, Stavitsky K, Harris E, et al. Mood, side of motor symptom onset and pain complaints in Parkinson’s disease. Int J Geriatr Psychiatry. 2010;25:519–24.CrossRefPubMed McNamara P, Stavitsky K, Harris E, et al. Mood, side of motor symptom onset and pain complaints in Parkinson’s disease. Int J Geriatr Psychiatry. 2010;25:519–24.CrossRefPubMed
17.
Zurück zum Zitat Greenbaum L, Tegeder I, Barhum Y, et al. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain. 2012;9:1243–50.CrossRef Greenbaum L, Tegeder I, Barhum Y, et al. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain. 2012;9:1243–50.CrossRef
20.
Zurück zum Zitat Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141:173–7.CrossRefPubMed Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141:173–7.CrossRefPubMed
22.
23.
Zurück zum Zitat Gierthmühlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson’s disease. Mov Disord. 2010;25:1195–202.CrossRefPubMed Gierthmühlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson’s disease. Mov Disord. 2010;25:1195–202.CrossRefPubMed
24.
Zurück zum Zitat de Ciampi AD, Lefaucheur JP, Galhardoni R, et al. Subthalamic deep brain stimulation modulates small fiber-dependent sensory thresholds in Parkinson’s disease. Pain. 2012;153:1107–13.CrossRef de Ciampi AD, Lefaucheur JP, Galhardoni R, et al. Subthalamic deep brain stimulation modulates small fiber-dependent sensory thresholds in Parkinson’s disease. Pain. 2012;153:1107–13.CrossRef
25.
Zurück zum Zitat Granovsky Y, Schlesinger I, Fadel S, Erikh I, Sprecher E, Yarnitsky D. Asymmetric pain processing in Parkinson’s disease. Eur J Neurol. 2013;20:1375–82.CrossRefPubMed Granovsky Y, Schlesinger I, Fadel S, Erikh I, Sprecher E, Yarnitsky D. Asymmetric pain processing in Parkinson’s disease. Eur J Neurol. 2013;20:1375–82.CrossRefPubMed
26.
Zurück zum Zitat Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord. 2008;23:1689–95.CrossRefPubMed Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord. 2008;23:1689–95.CrossRefPubMed
27.
Zurück zum Zitat Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60:3–38.CrossRefPubMed Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60:3–38.CrossRefPubMed
28.
Zurück zum Zitat Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–2.CrossRefPubMedPubMedCentral Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–2.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Perrotta A, Sandrini G, Serrao M, et al. Facilitated temporal summation of pain at spinal level in Parkinson’s disease. Mov Disord. 2011;26:442–8.CrossRefPubMed Perrotta A, Sandrini G, Serrao M, et al. Facilitated temporal summation of pain at spinal level in Parkinson’s disease. Mov Disord. 2011;26:442–8.CrossRefPubMed
30.
Zurück zum Zitat Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80:24–8.CrossRefPubMed Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80:24–8.CrossRefPubMed
31.
Zurück zum Zitat Brefel-Courbon C, Payoux P, Thalama C, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–63.CrossRefPubMed Brefel-Courbon C, Payoux P, Thalama C, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–63.CrossRefPubMed
32.
Zurück zum Zitat Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:548–52.CrossRefPubMed Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:548–52.CrossRefPubMed
33.
Zurück zum Zitat Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171–5.CrossRefPubMed Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171–5.CrossRefPubMed
34.
Zurück zum Zitat Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69:2162–9.CrossRefPubMed Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69:2162–9.CrossRefPubMed
35.
Zurück zum Zitat Tinazzi M, Del Vesco C, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson’s disease: a study with CO2 laser evoked potentials. Pain. 2008;136:117–24.CrossRefPubMed Tinazzi M, Del Vesco C, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson’s disease: a study with CO2 laser evoked potentials. Pain. 2008;136:117–24.CrossRefPubMed
36.
Zurück zum Zitat Tinazzi M, Recchia S, Simonetto S, et al. Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing. J Neurol Sci. 2009;276:153–8.CrossRefPubMed Tinazzi M, Recchia S, Simonetto S, et al. Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing. J Neurol Sci. 2009;276:153–8.CrossRefPubMed
37.
Zurück zum Zitat Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson’s disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord. 2010;25:213–20.CrossRefPubMed Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson’s disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord. 2010;25:213–20.CrossRefPubMed
38.
Zurück zum Zitat Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Möller JC. Pain sensitivity and clinical progression in Parkinson’s disease. Mov Disord. 2011;26:2220–5.CrossRefPubMed Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Möller JC. Pain sensitivity and clinical progression in Parkinson’s disease. Mov Disord. 2011;26:2220–5.CrossRefPubMed
39.
Zurück zum Zitat Conte A, Khan N, Defazio G, Rothwell JC, Berardelli A. Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol. 2013;9:687–97.CrossRefPubMed Conte A, Khan N, Defazio G, Rothwell JC, Berardelli A. Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol. 2013;9:687–97.CrossRefPubMed
40.
Zurück zum Zitat Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69:13–21.CrossRefPubMed Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69:13–21.CrossRefPubMed
41.
Zurück zum Zitat Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain. 2008;131:1903–11.CrossRefPubMed Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain. 2008;131:1903–11.CrossRefPubMed
42.
Zurück zum Zitat Kanda T, Tsukagoshi H, Oda M, Miyamoto K, Tanabe H. Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson’s disease and multiple system atrophy. Acta Neuropathol. 1996;91:145–54.CrossRefPubMed Kanda T, Tsukagoshi H, Oda M, Miyamoto K, Tanabe H. Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson’s disease and multiple system atrophy. Acta Neuropathol. 1996;91:145–54.CrossRefPubMed
43.
Zurück zum Zitat Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26:153–7.CrossRefPubMed Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26:153–7.CrossRefPubMed
44.
Zurück zum Zitat Nandhagopal R, Troiano AR, Mak E, Schulzer M, Bushnell MC, Stoessl AJ. Response to heat pain stimulation in idiopathic Parkinson’s disease. Pain Med. 2010;11:834–40.CrossRefPubMed Nandhagopal R, Troiano AR, Mak E, Schulzer M, Bushnell MC, Stoessl AJ. Response to heat pain stimulation in idiopathic Parkinson’s disease. Pain Med. 2010;11:834–40.CrossRefPubMed
45.
Zurück zum Zitat Spielberger S, Wolf E, Kress M, Seppi K, Poewe W. The influence of deep brain stimulation on pain perception in Parkinson’s disease. Mov Disord. 2011;26:1367–8.CrossRefPubMed Spielberger S, Wolf E, Kress M, Seppi K, Poewe W. The influence of deep brain stimulation on pain perception in Parkinson’s disease. Mov Disord. 2011;26:1367–8.CrossRefPubMed
46.
Zurück zum Zitat Dellapina E, Ory-Magne F, Regragui W, et al. Effect of subthalamic deep brain stimulation on pain in Parkinson’s disease. Pain. 2012;153:2267–73.CrossRefPubMed Dellapina E, Ory-Magne F, Regragui W, et al. Effect of subthalamic deep brain stimulation on pain in Parkinson’s disease. Pain. 2012;153:2267–73.CrossRefPubMed
47.
Zurück zum Zitat Vela L, Cano-de-la-Cuerda R, Fil A, Muñoz-Hellín E, Ortíz-Gutiérrez R, Macías-Macías Y, et al. Thermal and mechanical pain thresholds in patients with fluctuating Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:953–7.CrossRefPubMed Vela L, Cano-de-la-Cuerda R, Fil A, Muñoz-Hellín E, Ortíz-Gutiérrez R, Macías-Macías Y, et al. Thermal and mechanical pain thresholds in patients with fluctuating Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:953–7.CrossRefPubMed
48.
Zurück zum Zitat Marques A, Chassin O, Morand D, et al. Central pain modulation after subthalamic nucleus stimulation: a crossover randomized trial. Neurology. 2013;81:633–40.CrossRefPubMed Marques A, Chassin O, Morand D, et al. Central pain modulation after subthalamic nucleus stimulation: a crossover randomized trial. Neurology. 2013;81:633–40.CrossRefPubMed
49.
Zurück zum Zitat Chen Y, Mao CJ, Li SJ, et al. Quantitative and fiber-selective evaluation of pain and sensory dysfunction in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:361–5.CrossRefPubMed Chen Y, Mao CJ, Li SJ, et al. Quantitative and fiber-selective evaluation of pain and sensory dysfunction in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:361–5.CrossRefPubMed
50.
Zurück zum Zitat Vela L, Lyons KE, Singer C, Lieberman AN. Pain-pressure threshold in patients with Parkinson’s disease with and without dyskinesia. Parkinsonism Relat Disord. 2007;13:189–92.CrossRefPubMed Vela L, Lyons KE, Singer C, Lieberman AN. Pain-pressure threshold in patients with Parkinson’s disease with and without dyskinesia. Parkinsonism Relat Disord. 2007;13:189–92.CrossRefPubMed
51.
Zurück zum Zitat Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag. 2006;32:462–9.CrossRef Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag. 2006;32:462–9.CrossRef
52.
Zurück zum Zitat Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease. J Aging Res. 2011;2011, 232473.CrossRefPubMedPubMedCentral Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease. J Aging Res. 2011;2011, 232473.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Donoyama N, Ohkoshi N. Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson’s disease: a case-series study. J Altern Complement Med. 2012;18:294–9.CrossRefPubMed Donoyama N, Ohkoshi N. Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson’s disease: a case-series study. J Altern Complement Med. 2012;18:294–9.CrossRefPubMed
54.
Zurück zum Zitat Fénelon G, Goujon C, Gurruchaga JM, et al. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:213–4.CrossRefPubMed Fénelon G, Goujon C, Gurruchaga JM, et al. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:213–4.CrossRefPubMed
55.
Zurück zum Zitat Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012;116:99–106.CrossRefPubMed Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012;116:99–106.CrossRefPubMed
56.
Zurück zum Zitat Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:994–7.CrossRefPubMed Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:994–7.CrossRefPubMed
57.
Zurück zum Zitat Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83:1403–9.CrossRefPubMed Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83:1403–9.CrossRefPubMed
58.•
Zurück zum Zitat Kim YE, Lee WW, Yun JY, Yang HJ, Kim HJ, Jeon BS. Musculoskeletal problems in Parkinson’s disease: neglected issues. Parkinsonism Relat Disord. 2013;19:666–9. Kim et al. identified the prevalence and clinical features of musculoskeletal problems in patients with PD in their study enrolling 400 PD patients and 138 age- and sex-matched controls. They found a significantly greater prevalence of musculoskeletal problems in the PD group than in the control group (66.3% vs. 45.7%). The body parts commonly involved were the low back, knees, and shoulders. This study highlights the importance of evaluating musculoskeletal problems in people with PD.CrossRefPubMed Kim YE, Lee WW, Yun JY, Yang HJ, Kim HJ, Jeon BS. Musculoskeletal problems in Parkinson’s disease: neglected issues. Parkinsonism Relat Disord. 2013;19:666–9. Kim et al. identified the prevalence and clinical features of musculoskeletal problems in patients with PD in their study enrolling 400 PD patients and 138 age- and sex-matched controls. They found a significantly greater prevalence of musculoskeletal problems in the PD group than in the control group (66.3% vs. 45.7%). The body parts commonly involved were the low back, knees, and shoulders. This study highlights the importance of evaluating musculoskeletal problems in people with PD.CrossRefPubMed
59.
Zurück zum Zitat Sürücü O, Baumann-Vogel H, Uhl M, Imbach LL, Baumann CR. Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive pain in Parkinson’s disease. Pain. 2013;154:1477–9.CrossRefPubMed Sürücü O, Baumann-Vogel H, Uhl M, Imbach LL, Baumann CR. Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive pain in Parkinson’s disease. Pain. 2013;154:1477–9.CrossRefPubMed
60.•
Zurück zum Zitat Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson disease. JAMA Neurol. 2015;72:504–10. Jung et al. evaluated the long-term effects of STN-DBS in patients with PD and pain. This study demonstrated that STN-DBS can improve pain and that the effects persist after 8 years of follow-up.CrossRefPubMed Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson disease. JAMA Neurol. 2015;72:504–10. Jung et al. evaluated the long-term effects of STN-DBS in patients with PD and pain. This study demonstrated that STN-DBS can improve pain and that the effects persist after 8 years of follow-up.CrossRefPubMed
61.
Zurück zum Zitat Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study. Neurosurgery. 2012;70:18–23.CrossRefPubMed Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study. Neurosurgery. 2012;70:18–23.CrossRefPubMed
62.
Zurück zum Zitat Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral Pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91:198–201.CrossRefPubMed Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral Pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91:198–201.CrossRefPubMed
63.
Zurück zum Zitat Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol. 2008;255:1889–94.CrossRefPubMed Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol. 2008;255:1889–94.CrossRefPubMed
64.
Zurück zum Zitat Pellaprat J, Ory-Magne F, Canivet C, et al. Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:662–4.CrossRefPubMed Pellaprat J, Ory-Magne F, Canivet C, et al. Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:662–4.CrossRefPubMed
65.
Zurück zum Zitat Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson’s disease. Clin Neurol Neurosurg. 2011;113:11–3.CrossRefPubMed Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson’s disease. Clin Neurol Neurosurg. 2011;113:11–3.CrossRefPubMed
66.
Zurück zum Zitat de Rodrigues PF, Teixeira-Salmela LF, de Coelho MFCD, de Rocha BP, Cardoso F. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord. 2006;21:1073–7.CrossRef de Rodrigues PF, Teixeira-Salmela LF, de Coelho MFCD, de Rocha BP, Cardoso F. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord. 2006;21:1073–7.CrossRef
67.
Zurück zum Zitat Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord. 2002;17:799–802.CrossRefPubMed Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord. 2002;17:799–802.CrossRefPubMed
68.
Zurück zum Zitat Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task force. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70.CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task force. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70.CrossRefPubMed
69.
Zurück zum Zitat Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2015. Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2015.
70.
Zurück zum Zitat Clark WC, Yang JC, Tsui SL, Ng KF, Bennett CS. Unidimensional pain rating scales: a multidimensional affect and pain survey (MAPS) analysis of what they really measure. Pain. 2002;98:241–7.CrossRefPubMed Clark WC, Yang JC, Tsui SL, Ng KF, Bennett CS. Unidimensional pain rating scales: a multidimensional affect and pain survey (MAPS) analysis of what they really measure. Pain. 2002;98:241–7.CrossRefPubMed
71.
Zurück zum Zitat Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs. 2012;17:157–71.CrossRefPubMed Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs. 2012;17:157–71.CrossRefPubMed
72.
Zurück zum Zitat Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease. J Neural Transm. 2010;117:837–46.CrossRefPubMed Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease. J Neural Transm. 2010;117:837–46.CrossRefPubMed
73.
Zurück zum Zitat Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009;24:1233–7.CrossRefPubMed Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009;24:1233–7.CrossRefPubMed
74.
Zurück zum Zitat Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.CrossRefPubMed Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.CrossRefPubMed
75.
Zurück zum Zitat Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000;15:167–9.CrossRefPubMed Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000;15:167–9.CrossRefPubMed
76.
Zurück zum Zitat Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.CrossRefPubMedPubMedCentral Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.CrossRefPubMedPubMedCentral
77.
Zurück zum Zitat Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain inpatients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14–42. Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain inpatients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14–42.
78.
Zurück zum Zitat Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010;289:60–5.CrossRefPubMed Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010;289:60–5.CrossRefPubMed
79.
Zurück zum Zitat Ghoche R. The conceptual framework of palliative care applied to advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:S2–5.CrossRefPubMed Ghoche R. The conceptual framework of palliative care applied to advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:S2–5.CrossRefPubMed
80.
Zurück zum Zitat Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201–5.PubMed Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201–5.PubMed
81.
Zurück zum Zitat Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16:907–13.CrossRefPubMed Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16:907–13.CrossRefPubMed
82.
Zurück zum Zitat Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007;22:2097–103.CrossRefPubMed Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007;22:2097–103.CrossRefPubMed
83.•
Zurück zum Zitat Tassorelli C, De Icco R, Alfonsi E, et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014;20:1140–4. Tassorelli et al. evaluated the effects of BTX type A in reducing hyperactive trunk muscles and enhancing the rehabilitation intervention. Their preliminary data suggest that BTX type A in conjunction with a rehabilitation program may improve axial posture and trunk mobility, as well as pain symptoms. This study highlights the importance of an integrated approach to managing motor and nonmotor symptoms in PD patients.CrossRefPubMed Tassorelli C, De Icco R, Alfonsi E, et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014;20:1140–4. Tassorelli et al. evaluated the effects of BTX type A in reducing hyperactive trunk muscles and enhancing the rehabilitation intervention. Their preliminary data suggest that BTX type A in conjunction with a rehabilitation program may improve axial posture and trunk mobility, as well as pain symptoms. This study highlights the importance of an integrated approach to managing motor and nonmotor symptoms in PD patients.CrossRefPubMed
85.
Zurück zum Zitat Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:395–9.CrossRefPubMedPubMedCentral Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:395–9.CrossRefPubMedPubMedCentral
86.
Zurück zum Zitat Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345:956–63.CrossRef Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345:956–63.CrossRef
87.
Zurück zum Zitat Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease. Mov Disord. 2007;22:1729–34.CrossRefPubMed Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease. Mov Disord. 2007;22:1729–34.CrossRefPubMed
88.
Zurück zum Zitat Maruo T, Saitoh Y, Hosomi K, et al. Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson’s disease. Pain. 2011;152:860–5.CrossRefPubMed Maruo T, Saitoh Y, Hosomi K, et al. Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson’s disease. Pain. 2011;152:860–5.CrossRefPubMed
89.
Zurück zum Zitat Ogino Y, Nemoto H, Inui K, Saito S, Kakigi R, Goto F. Inner experience of pain: imagination of pain while viewing images showing painful events forms subjective pain representation in human brain. Cereb Cortex. 2007;17:1139–46.CrossRefPubMed Ogino Y, Nemoto H, Inui K, Saito S, Kakigi R, Goto F. Inner experience of pain: imagination of pain while viewing images showing painful events forms subjective pain representation in human brain. Cereb Cortex. 2007;17:1139–46.CrossRefPubMed
90.
Zurück zum Zitat Hodges PW. Pain and motor control: from the laboratory to rehabilitation. J Electromyogr Kinesiol. 2011;21:220–8.CrossRefPubMed Hodges PW. Pain and motor control: from the laboratory to rehabilitation. J Electromyogr Kinesiol. 2011;21:220–8.CrossRefPubMed
91.
Zurück zum Zitat Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg. 1992;76:53–61.CrossRefPubMed Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg. 1992;76:53–61.CrossRefPubMed
92.
Zurück zum Zitat Oakley JC, Prager JP. Spinal cord stimulation: mechanisms of action. Spine (Phila Pa 1976). 2002;27:2574–83.CrossRef Oakley JC, Prager JP. Spinal cord stimulation: mechanisms of action. Spine (Phila Pa 1976). 2002;27:2574–83.CrossRef
94.
Zurück zum Zitat Allen NE, Moloney N, van Vliet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J Parkinsons Dis. 2015. Allen NE, Moloney N, van Vliet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J Parkinsons Dis. 2015.
95.
Zurück zum Zitat Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s disease. Neurology. 2001;57:790–4.CrossRefPubMed Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s disease. Neurology. 2001;57:790–4.CrossRefPubMed
96.
Zurück zum Zitat Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69:119–30.CrossRefPubMed Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69:119–30.CrossRefPubMed
Metadaten
Titel
Integrated Approach for Pain Management in Parkinson Disease
verfasst von
Christian Geroin
Marialuisa Gandolfi
Veronica Bruno
Nicola Smania
Michele Tinazzi
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 4/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0628-7

Weitere Artikel der Ausgabe 4/2016

Current Neurology and Neuroscience Reports 4/2016 Zur Ausgabe

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurologic Complications of Commonly Used Drugs in the Hospital Setting

Headache (R. B. Halker, Section Editor)

Managing Migraine During Pregnancy and Lactation

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.